| Identification | Back Directory | [Name]
Methanone, 1-piperidinyl[4,5,6,7-tetrahydro-1-propyl-5-[[2-(4-pyridinyl)ethyl]amino]-1H-indazol-3-yl]-, hydrochloride (1:2) | [CAS]
2749281-71-6 | [Synonyms]
Methanone, 1-piperidinyl[4,5,6,7-tetrahydro-1-propyl-5-[[2-(4-pyridinyl)ethyl]amino]-1H-indazol-3-yl]-, hydrochloride (1:2) | [Molecular Formula]
C23H34ClN5O | [MOL File]
2749281-71-6.mol | [Molecular Weight]
432.01 |
| Hazard Information | Back Directory | [Uses]
NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046)[1]. NUCC-390 dihydrochloride promotes nerve recovery of function after neurodegeneration in vivo[2]. | [in vivo]
NUCC-390 dihydrochloride (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice[2]. | Animal Model: | Six to eight-week-old CD1 mice[2] | | Dosage: | 3.2 mg/kg | | Administration: | Hind limb injection; twice daily; 3 days | | Result: | Promoted functional and anatomical recovery of the NMJ. |
| [IC 50]
CXCR4 | [References]
[1] Mishra RK, et al. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.Sci Rep. 2016 Jul 26;6:30155. DOI:10.1038/srep30155 |
|
|